Question 1

What amounts of CJC-1295 did the published studies use?

Accepted Answer

Amounts scaled to body weight, in a design built to climb from small to large. The 2006 report describes two randomized, placebo-controlled, double-blind, ascending dose trials, ascending dose meaning that each group received a larger amount than the one before it, so that problems would show early at the bottom of the ladder. The summary names only two of those amounts. Its conclusion singles out the injections as best received particularly at doses of 30 or 60 microg/kg, where microg/kg means micrograms for each kilogram of the person's weight. The other rungs of the ladder are not given in the abstract. That gap matters more than it might seem, because a figure presented as the CJC-1295 dose usually arrives without the context that it was one step in a safety ladder for healthy volunteers. The authors' preference for those two amounts was a judgment about tolerance in a short trial, rather than evidence that either amount does anything a person would notice, since hormone levels in blood were the only outcome measured.

Question 2

Who received the CJC-1295 trial amounts?

Accepted Answer

Screened healthy adults, and almost nobody else, since the report states that healthy subjects, ages 21-61 yr, were studied. It adds that the study was performed at two investigational sites., which means a few clinics gave the shots and took the blood. A second, smaller study used the compound for a different purpose, analysing sera from 11 healthy young adult men before and one week after CJC-1295 injection, serum being the clear part of blood, for protein markers of growth hormone activity, so a single injection in eleven men followed by a laboratory analysis constitutes the whole of that exposure. The trial that would have taken the record to patients did not finish. So every published amount went to people picked because nothing was wrong with them, who were then watched closely for a few weeks. An amount set in that group does not carry over to someone with an illness, an older body or a different goal.

Question 3

Why was CJC-1295 built to be given weekly?

Accepted Answer

Because the natural hormone it copies wears off too fast to be of much use. The 2006 report names that problem in its first line: therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action. GHRH is growth hormone-releasing hormone, the brain's own signal to the pituitary. The fix was chemical. A 2019 lab paper explains that CJC-1295 incorporates a functional maleimido group at the C-terminus that allows it to covalently bind plasma proteins such as serum albumin, albumin being the most common protein in blood. Once bound, the molecule stays in the blood for days. The trials then measured its pharmacokinetics, meaning how the body absorbs and clears it, and found that the estimated half-life of CJC-1295 was 5.8-8.1 d. A half-life of about a week is what makes a weekly or fortnightly schedule possible at all. That is a trait of the molecule rather than advice, and the weekly spacing in the trials came from it rather than from a test of which gap works best.

Question 4

Did larger amounts give larger effects?

Accepted Answer

Yes, for hormone concentrations in blood, which were the only outcomes the trials measured. After a single injection the report found dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more, dose-dependent meaning that larger amounts produced proportionally larger increases. The breadth of that range deserves attention, because a two-fold increase and a ten-fold increase represent very different exposures, and the summary connects the magnitude of the rise to the size of the amount without providing a figure for each step. What it does make explicit is what the trials were measuring, since the main outcome measures were peak concentrations and area under the curve of GH and IGF-I. Area under the curve represents the total exposure accumulated over time. Larger amounts therefore produced more hormone, and that is where the finding ends. Whether additional hormone translates into more muscle, less fat or better sleep was never examined in these trials, so a dose-response relationship for blood concentrations does not tell anyone which amount, if any, changes how a body looks or feels.

Question 5

Does a second dose add to the first?

Accepted Answer

It appears to, and that observation is one of the few repeated-dose findings on record. The second 2006 trial gave two or three weekly or biweekly doses, biweekly here meaning every two weeks, and the authors reported that there was evidence of a cumulative effect after multiple doses. A cumulative effect means each injection began from a level the previous one had not fully released. With a half-life near a week, a second dose given seven days after the first arrives while roughly half of the first is still circulating, which is the arithmetic of a long-acting molecule and the reason spacing matters more for this compound than for short-acting ones. What the summary does not provide is the size of the accumulation at each interval, or whether it plateaus. It does report that after multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d. Spacing doses more closely than the trials did would enter exposure that no study among these sources has measured, and since the trials stopped at three doses, anything beyond that lies outside the published record rather than extending it.

Question 6

What does a dose in micrograms per kilogram mean?

Accepted Answer

It means the amount was scaled to each person's weight rather than fixed. The trial amounts, written as doses of 30 or 60 microg/kg, are instructions to multiply by body weight, so a heavier volunteer received more compound than a lighter one at the same step. That makes the published figures hard to compare with anything sold. Vials are labelled in total milligrams or micrograms, while the trials were written per kilogram, and the two cannot be matched without a body weight. This page does not do that sum for anybody, because a per-kilogram figure multiplied out for a reader's own weight is a personal dose in all but name. The units also differ by a factor of a thousand. A microgram is a thousandth of a milligram, so the trial amounts are small numbers in micrograms per kilogram, while vial labels run to milligrams. A 2026 review of growth hormone axis peptides names the uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains, and confusion between units is one of the ways that uncertainty arises rather than a separate problem.

Question 7

Is there a CJC-1295 dosage chart?

Accepted Answer

Not one that comes from a trial. Charts do circulate, and a 2026 review written for doctors who see patients using these compounds sets them against the evidence. Its authors describe how the review contrasts peer-reviewed pharmacokinetic/pharmacodynamic and clinical evidence with commonly encountered online self-administration protocols, setting what was measured against what circulates. The same review is careful about its own purpose. It summarises commonly reported dosing patterns so that doctors can recognise them, and it frames its advice as risk communication without legitimising off-label peptide regimens. Saying that a pattern exists is not the same as backing it. The published record could fill only two rows of an honest chart: a single injection at a weight-scaled amount, and two or three injections a week or two apart, both in healthy volunteers watched for hormone levels. Anything longer has been assembled from somewhere other than those trials, and this page does not reproduce it, because a chart copied without its source carries authority it has not earned.

Question 8

Does the version without DAC have a published schedule?

Accepted Answer

No schedule among the research behind this page belongs to it, and the two forms are treated as distinct compounds by the researchers who study them. A 2026 review lists CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC as separate entries, DAC being the chemical attachment that binds the molecule to albumin in the blood. That attachment is what determines the timing, and the 2019 analytical paper reports that the bound forms have a much greater half-life compared to the unconjugated peptide, unconjugated meaning without the attachment. A schedule designed for a molecule lasting about a week therefore does not suit one that is cleared far more rapidly. Every published half-life and every trial schedule here describes the long-acting form. Applying a weekly spacing to the version without DAC would mean using a timetable built for a different molecule, rather than one anybody has tested for this one. How long that version lasts in a person is simply not reported in the sources covered here.

Question 9

What do CJC-1295 vial labels show?

Accepted Answer

The FDA recall record is the one public source that prints them, and two single-compound labels appear there. One was CJC-1295, 2000 MCG/ML, 5 ML vial, already dissolved. Its total follows by multiplication: 2,000 micrograms in each millilitre, times five millilitres, is 10,000 micrograms, or 10 mg. On a U-100 insulin syringe each unit mark is a hundredth of a millilitre, so at 2,000 micrograms per millilitre one unit carries 20 micrograms and ten units carry 200. That conversion holds for any amount a person decides on, and it says nothing about which amount to decide on, because no study among these sources set one for use outside a trial. The second label is harder to read. It describes CJC-1295 Injectable, 6mg/15mg, pre-filled syringe, and the record does not explain what the two figures mean. Both items were withdrawn for lack of sterility assurance. The calculator at the reconstitution calculator runs these conversions on any label without proposing a target.

Question 10

Is there a cycle or a break in the published work?

Accepted Answer

No study among the research behind this page tested a cycle, so the published record contains courses rather than cycles: the two trials lasted 28 and 49 days, with no planned interruption and no second course. The question has nevertheless been raised, by users rather than by researchers, and a 2016 study of online forums about women's use of CJC-1295 found concerns about estimation of dosage, cycling, and long-term consequences, which forum participants connected to differences in how growth hormone pulses in women and men. That is a record of people constructing schedules among themselves in the absence of a published one. The reviews treat it as open. A 2026 review of peptides in ageing lists optimal dosing regimens among the significant knowledge gaps for compounds including CJC-1295. With a half-life near a week and IGF-I remaining elevated for up to four weeks after the final dose, a break would also take longer to become a genuine break than it would for a short-acting compound. Whether any cycle alters the response has not been asked, which is different from being answered in favour of cycling.

Question 11

Was a dose ever tested in patients?

Accepted Answer

One trial set out to, and it did not finish. The public registry holds A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity, a phase 2 study, visceral obesity being fat stored around the organs. Its recorded status is TERMINATED. The registry entry among these sources gives no amount and no reason for stopping, and no published results from it appear among the research behind this page. So the one attempt to find a working amount in people with a condition left no figure behind. That leaves the 2006 trials as the whole human dosing record. Their authors ended on a forward-looking note, writing that these data support the potential utility of CJC-1295 as a therapeutic agent. Potential utility is what a phase 1 result offers, and the trial that would have tested it did not reach a result. A 2026 structured review still classes CJC-1295 among compounds that remain investigational.

Question 12

Why is a CJC-1295 trial amount not a protocol?

Accepted Answer

Because the trials were built to measure blood levels in volunteers, and a protocol needs proof that an amount does some good. A 2026 primer for bone and sports doctors states where CJC-1295 and its relatives stand: information regarding the indications, dosing, frequency, and duration of treatment remains unknown. Every element of a protocol appears in that list. The gap between study and use goes further. A 2026 critical review of peptides in sport notes that published work does not cover the supraphysiological or combined protocols common in bodybuilding, supraphysiological meaning above the body's natural range. A 2026 structured review in sports medicine concludes that clinical use should be confined to approved metabolic agents for indicated conditions and to rigorously designed research protocols. So the amounts on this page are study settings with a known context: healthy adults, a few weeks, and hormone levels as the outcome. They describe what was given rather than what to take, and that is the only reason they are set out here at all.

CJC-1295 protocols in the published literature